H. Westley Phillips, MD, joined us to provide clinical pearls regarding the early identification of drug-resistant epilepsy patients in the primary care setting. Drug-resistant epilepsy remains a ...
The application indication is for adults and pediatric patients aged 12 years and older with CSU whose disease is not adequately controlled with H1 antihistamines. The FDA has accepted the resubmitted ...
With this expanded FDA clearance, the wearable becomes the first FDA-cleared, non-drug therapy to treat acute migraines in children. According to a recent announcement from Theranica, the Nerivio ...
A discussion of tips and recommendations general providers can use when evaluating ADHD in pediatric patients. Pediatricians play a vital role in the management of ...
Among extremely preterm infants who were receiving surfactant, early intratracheal budesonide could have little to no effect on survival free of bronchopulmonary dysplasia (BPD), according to findings ...
A resubmission Biologics License Application for prademagene zamikeracel (pz-cel) as a potential treatment for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted by the FDA, according ...
With the decision, Kebilidi becomes the first FDA-approved gene therapy for AADC deficiency, and is indicated for adult and pediatric patients. The first gene therapy for for the treatment of aromatic ...
Rakesh Jain, MD, MPH discusses once-daily clonidine hydrochloride (ONYDA XR) for ADHD ...
Rakesh Jain, MD, MPH discusses once-daily clonidine hydrochloride (ONYDA XR) for ADHD ...
Rakesh Jain, MD, MPH discusses once-daily clonidine hydrochloride (ONYDA XR) for ADHD ...
Rakesh Jain, MD, MPH discusses once-daily clonidine hydrochloride (ONYDA XR) for ADHD ...
Rakesh Jain, MD, MPH discusses once-daily clonidine hydrochloride (ONYDA XR) for ADHD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback